MS
AUTL

Maven Securities’s Autolus Therapeutics AUTL Stock Holding History

Maven Securities’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-20,000
Closed -$511K – 152
2018
Q2 		$511K Buy
+20,000
New +$529K 0.28% 54

Other funds holding AUTL

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Maven Securities's AUTL Position: Q3 2018 in Review

Maven Securities sold out of Autolus Therapeutics (AUTL) in Q3 2018, closing a stake of 20,000 shares — an estimated $511K sold.

Maven Securities first reported a position in AUTL in Q2 2018 and held it in 1 quarter. The position peaked at $511K in Q2 2018. 39 funds tracked by Wall St. Rank hold AUTL as of Q3 2018.

  • Maven Securities reported no remaining Autolus Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Maven Securities sold 20,000 Autolus Therapeutics shares in Q3 2018, an estimated $511K.
  • Maven Securities first reported a position in Autolus Therapeutics in Q2 2018 and held it in 1 quarter.
  • Maven Securities's Autolus Therapeutics position peaked at $511K in Q2 2018.
  • 39 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2018.

Based on Maven Securities's 13F filing for Q3 2018, filed 14 Nov 2018.